Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at biopharmadive.com →

More in Health & Medicine

More from Wednesday 18 November →